We are live on
!
Find out more
AA
ALPS Advisors Portfolio holdings
AUM
$21.3B
1-Year Est. Return
21.71%
This Fund
S&P 500
This Quarter
Est. Return
+0.76%
1 Year Est. Return
+21.71%
3 Year Est. Return
+77.63%
5 Year Est. Return
+121.1%
10 Year Est. Return
+198.29%
AUM
$13.6B
AUM Growth
+$1.31B
(+11%)
Cap. Flow
+$1.24B
Cap. Flow
% of AUM
9.18%
Top 10 Holdings %
Top 10 Hldgs %
52.17%
Holding
753
New
79
Increased
425
Reduced
211
Closed
38
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ETP
Energy Transfer Partners L.p.
ETP
|
+$190M |
| 2 |
Enterprise Products Partners
EPD
|
+$96.4M |
| 3 |
MMP
Magellan Midstream Partners, L.P.
MMP
|
+$94.8M |
| 4 |
Plains All American Pipeline
PAA
|
+$81.9M |
| 5 |
BPL
Buckeye Partners, L.P.
BPL
|
+$76.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nucor
NUE
|
+$36.6M |
| 2 |
NOV
NOV
|
+$34.2M |
| 3 |
Qualcomm
QCOM
|
+$34.1M |
| 4 |
CenterPoint Energy
CNP
|
+$32.7M |
| 5 |
ConocoPhillips
COP
|
+$31.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 67.49% |
| 2 | Financials | 2.86% |
| 3 | Materials | 2.35% |
| 4 | Healthcare | 2.33% |
| 5 | Industrials | 1.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ADAP
676
DELISTED
Adaptimmune Therapeutics
ADAP
| $275K | ﹤0.01% |
+68,024
| New | +$326K |
|
|
OMED
677
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $275K | ﹤0.01% |
35,645
-10,102
| -22% | -$92.8K |
|
|
678
Nucor
NUE
$56.4B
| $271K | ﹤0.01% |
4,558
-654,959
| -99% | -$36.6M |
|
679
Acadia Healthcare
ACHC
$3.17B
| $270K | ﹤0.01% |
8,172
+77
| +1% | +$2.99K |
|
680
McDonald's
MCD
$188B
| $264K | ﹤0.01% |
+2,171
| New | +$255K |
|
681
American International
AIG
$41.9B
| $260K | ﹤0.01% |
3,974
-141
| -3% | -$8.85K |
|
|
NE
682
DELISTED
Noble Corporation
NE
| $257K | ﹤0.01% |
43,356
+25,827
| +147% | +$152K |
|
683
WisdomTree
WT
$2.97B
| $251K | ﹤0.01% |
+22,540
| New | +$235K |
|
684
Cencora
COR
$60.3B
| $250K | ﹤0.01% |
+3,199
| New | +$250K |
|
|
EQGP
685
DELISTED
EQGP Holdings, LP
EQGP
| $247K | ﹤0.01% |
9,807
+489
| +5% | +$11.8K |
|
686
Expeditors International
EXPD
$22.9B
| $243K | ﹤0.01% |
+4,585
| New | +$240K |
|
|
WDR
687
DELISTED
Waddell & Reed Financial, Inc.
WDR
| $239K | ﹤0.01% |
+12,258
| New | +$228K |
|
688
Leidos
LDOS
$14.1B
| $233K | ﹤0.01% |
+4,549
| New | +$213K |
|
689
Advanced Micro Devices
AMD
$851B
| $227K | ﹤0.01% |
+19,998
| New | +$168K |
|
690
Tesla
TSLA
$1.24T
| $224K | ﹤0.01% |
+15,735
| New | +$207K |
|
|
CNCE
691
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $220K | ﹤0.01% |
21,406
-6,930
| -24% | -$63.3K |
|
|
AGN
692
DELISTED
Allergan plc
AGN
| $219K | ﹤0.01% |
+1,042
| New | +$216K |
|
693
Microchip Technology
MCHP
$42.8B
| $216K | ﹤0.01% |
+6,738
| New | +$212K |
|
|
WIN
694
DELISTED
Windstream Holdings Inc
WIN
| $210K | ﹤0.01% |
5,730
+3,328
| +139% | +$130K |
|
|
FIT
695
DELISTED
Fitbit, Inc. Class A common stock
FIT
| $208K | ﹤0.01% |
28,423
+269
| +1% | +$2.75K |
|
|
CMRX
696
DELISTED
Chimerix, Inc.
CMRX
| $205K | ﹤0.01% |
44,508
-14,406
| -24% | -$68K |
|
697
Ocular Therapeutix
OCUL
$1.86B
| $200K | ﹤0.01% |
23,909
-7,734
| -24% | -$60K |
|
|
TWTR
698
DELISTED
Twitter, Inc.
TWTR
| $182K | ﹤0.01% |
11,138
+275
| +3% | +$5.04K |
|
|
CLSD
699
DELISTED
Clearside Biomedical
CLSD
| $177K | ﹤0.01% |
+1,318
| New | +$331K |
|
700
Bausch Health
BHC
$1.65B
| $170K | ﹤0.01% |
+11,691
| New | +$214K |
|
Similar funds
PAG
MMH
IC
DSA
VARA
SC
CB
ALPS Advisors's Q4 2016 Portfolio in Review
As of Q4 2016, ALPS Advisors held 753 positions worth $13.6B, up 11% from $12.3B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
ALPS Advisors deployed $1.24B of net new capital in Q4 2016, opening 79 new positions and adding to 425 existing holdings. Its largest new stake was Eli Lilly: 558,209 shares worth $41.1M.
By sector, the portfolio is most concentrated in Energy at 67% of assets, up from 66% a quarter earlier, followed by Financials and Materials.
On the sell side, the largest reduction was Nucor, an estimated $36.6M trimmed.
- ALPS Advisors's largest Q4 2016 buy was Eli Lilly: 558,209 shares worth $41.1M.
- ALPS Advisors added most to Energy Transfer Partners L.p. in Q4 2016, an estimated $190M increase.
- ALPS Advisors's biggest Q4 2016 reduction was Nucor, cutting an estimated $36.6M.
- ALPS Advisors fully exited NOV in Q4 2016, selling an estimated $34.2M.
- ALPS Advisors's ten largest holdings make up 52% of its $13.6B portfolio in Q4 2016.
- ALPS Advisors opened 79 new positions and closed 38 in Q4 2016.
- ALPS Advisors's portfolio value rose 11% quarter-over-quarter to $13.6B.
Based on ALPS Advisors's 13F filing for Q4 2016, filed 24 Jan 2017.